Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DLV0Z8
|
|||
| Drug Name |
REMD 477
|
|||
| Synonyms |
Volagidemab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 1/2 | [2] | ||
| Type-2 diabetes [ICD-11: 5A11] | Phase 1/2 | [3] | ||
| Company |
REMD Biotherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon receptor (GCGR) | Target Info | Antagonist | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glucagon signaling pathway | ||||
| Reactome | Glucagon signaling in metabolic regulation | |||
| G alpha (q) signalling events | ||||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03117998) Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 4 | Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.